



March 1, 2019

Phadia AB
% Sheryl Skinner
Regulatory Director, RA/QA
Phadia US Inc.
4169 Commercial Avenue
Portage, Michigan 49002

Re: K181871

Trade/Device Name: EliA Celikey IgG Immunoassay; EliA GliadinDP IgA Immunoassay; EliA GliadinDP IgG Immunoassay

Regulation Number: 21 CFR 866.5660

Regulation Name: Multiple autoantibodies immunological test system

Regulatory Class: Class II

Product Code: MVM, MST

Dated: July 10, 2018

Received: July 12, 2018

Dear Sheryl Skinner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/>) and CDRH Learn (<http://www.fda.gov/Training/CDRHLearn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<http://www.fda.gov/DICE>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,


Douglas A. Jeffery -S

Doug Jeffery, Ph.D.
Branch Chief
Immunology and Flow Cytometry Branch
Division of Immunology
and Hematology Devices
Office of In Vitro Diagnostics
and Radiological Health
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K181871

Device Name

EliA Celikey IgG Immunoassay, EliA GliadinDP IgA Immunoassay, EliA GliadinDP IgG Immunoassay

Indications for Use (Describe)

EliA Celikey IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to tissue transglutaminase (tTG) in human serum and EDTA-plasma. EliA Celikey IgG is based on recombinant human tissue transglutaminase as antigen and is useful as an aid in the clinical diagnosis of patients with celiac disease in conjunction with other laboratory and clinical findings. EliA Celikey IgG uses the EliA IgG method on the instrument Phadia 2500/5000.

EliA GliadinDP IgA is intended for the in vitro semi-quantitative measurement of IgA antibodies directed to gliadin in human serum or plasma (Li-heparin, EDTA) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA GliadinDP IgA uses the EliA IgA method on the instrument Phadia 2500/5000.

EliA GliadinDP IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to gliadin in human serum or plasma (Li-heparin, EDTA) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA GliadinDP IgG uses the EliA IgG method on the instrument Phadia 2500/5000.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

A.6 510(k) Summary of Safety and Effectiveness per 21CFR 807.92(c).

This summary of safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR Part 807.92.

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY AND INSTRUMENT COMBINATION TEMPLATE

A. 510(k) Number: K181871

B. Purpose for Submission:

Adding previously cleared assays on a new instrument platform (Phadia® 2500/5000)

C. Measurands:

Anti-tissue transglutaminase (tTG) IgG antibody
Anti-gliadin IgA and anti-gliadin IgG autoantibodies

D. Type of Test:

Semi-quantitative measurement immunoassays

E. Applicant:

Phadia AB
Rapsgatan 7P
P.O. Box 6460
SE-751 37 Uppsala, Sweden
Tel: +46-18-16 50 60

510(k) Contact Person:

Sheryl Skinner
Associate Director, RA/QA
ImmunoDiagnostics US
Thermo Fisher Scientific
Phadia US Inc.
4169 Commercial Avenue
Portage, MI 49002, USA
Tel. 269.568.3603
sheryl.skinner@thermofisher.com

Date of Summary Preparation: February 28, 2019

F. Proprietary and Established Names:

EliA Celikey IgG Immunoassay
EliA Gliadin^{DP} IgA Immunoassay
EliA Gliadin^{DP} IgG Immunoassay

G. Regulatory Information:

1. Regulation section:

- 21 CFR §866.5660 Multiple autoantibodies immunological test system
- 21 CFR §866.5750 – Radioallergosorbent (RAST) Immunological Test System

2. Classification:

Class II

3. Product code:

- | | |
|-----|--|
| MVM | Autoantibodies, endomysial (tissue transglutaminase) |
| MST | autoantibodies, gliadin |

4. Panel: Immunology (82)

H. Intended use(s):

1. Intended use(s):

EliA Celikey IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to tissue transglutaminase (tTG) in human serum and EDTA-plasma. EliA Celikey IgG is based on recombinant human tissue transglutaminase as antigen and is useful as an aid in the clinical diagnosis of patients with celiac disease in conjunction with other laboratory and clinical findings. EliA Celikey IgG uses the EliA IgG method on the instrument Phadia 2500/5000.

EliA Gliadin^{DP} IgA is intended for the in vitro semi-quantitative measurement of IgA antibodies directed to gliadin in human serum or plasma (Li-heparin, EDTA) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA Gliadin^{DP} IgA uses the EliA IgA method on the instrument Phadia 2500/5000.

EliA Gliadin^{DP} IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to gliadin in human serum or plasma (Li-heparin, EDTA) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA Gliadin^{DP} IgG uses the EliA IgG method on the instrument Phadia 2500/5000.

2. Indication(s) for use:

Same as intended use

3. Special conditions for use statement(s):

For prescription use only

4. Special instrument requirements:

Performance studies were obtained from the Phadia® 2500/5000 instrument
This device is not for point-of-care use.

I. Device Description:

The method-specific reagents are identical with K062583 (EliA Celikey IgG) and K093459 (EliA Gliadin^{DP} IgA and EliA Gliadin^{DP} IgG), but are filled in containers specific for the Phadia 2500/5000 instrument. Each device consists of:

Test Wells:

- EliA Celikey IgG Wells are coated with human recombinant tissue transglutaminase (tTG) – 2 carriers (12 wells each), ready to use;
- EliA Gliadin^{DP} IgA Wells are coated with synthetic deamidated gliadin peptides – 4 carriers (12 wells each), ready to use;
- EliA Gliadin^{DP} IgG Wells are coated with synthetic deamidated gliadin peptides – 4 carriers (12 wells each), ready to use;

EliA Sample Diluent:

- EliA Sample Diluent: PBS containing BSA, detergent and 0.095% (w/v) sodium azide – 6 bottles, 48 mL each, ready to use; or 6 bottles, 400 mL each, ready to use;

EliA IgG reagents (required for EliA Celikey IgG and EliA Gliadin^{DP} IgG):

- EliA IgG Conjugate 50 or 200: β -Galactosidase labeled anti-IgG (mouse monoclonal antibodies) in PBS containing BSA and 0.06% (w/v) sodium azide – 6 wedge shaped bottles, 5 mL each, ready to use; or 6 wedge shaped bottles, 19 mL each, ready to use
- EliA IgG Calibrator Strips: Human IgG (0, 4, 10, 20, 100, 600 μ g/L) in PBS containing BSA, detergent and 0.095% (w/v) sodium azide – 5 strips, 6 single-use vials per strip, 0.3 mL each, ready to use;
- EliA IgG Curve Control Strips: Human IgG (20 μ g/L) in PBS containing BSA, detergent and 0.095% (w/v) sodium azide – 5 strips, 6 single-use vials per strip, 0.3 mL each, ready to use;
- EliA IgG Calibrator Well: Coated with mouse monoclonal antibodies – 4 carriers (12 wells each), ready to use.

EliA IgA reagents (required for EliA Gliadin^{DP} IgA):

- EliA IgA Conjugate 50 or 200: β -Galactosidase labeled anti-IgA (mouse monoclonal antibodies) in PBS containing BSA and 0.06% (w/v) sodium azide – 6 wedge shaped bottles, 5 mL each, ready to use; or 6 wedge shaped bottles, 19 mL each, ready to use
- EliA IgA Calibrator Strips: Human IgA (0, 0.3, 1.5, 5, 15, 80 μ g/L) in PBS containing BSA, detergent and 0.095% (w/v) sodium azide – 5 strips, 6 single-use vials per strip, 0.3 mL each, ready to use;
- EliA IgA Curve Control Strips: Human IgA (20 μ g/L) in PBS containing BSA, detergent and 0.095% (w/v) sodium azide – 5 strips, 6 single-use vials per strip, 0.3 mL each, ready to use;
- EliA IgA Calibrator Well: Coated with mouse monoclonal antibodies – 4 carriers (12 wells each), ready to use.

The Phadia EliA Immunodiagnostic System is an automated system for immunodiagnostic testing. The EliA reagents are available as modular packages, each purchased separately. All packages are required to carry out EliA Celikey IgG and EliA Gliadin^{DP} IgA and EliA Gliadin^{DP} IgG tests.

J. Substantial Equivalence Information:

1. Predicate device name(s) and 510(k) number(s):

EliA Celikey IgG on Phadia 250 instrument, K062583

EliA Gliadin^{DP} IgA on Phadia 250 instrument, K093459

EliA Gliadin^{DP} IgG on Phadia 250 instrument, K093459

2. Comparison with predicate device:

EliA Celiac Immunoassays on Phadia 250 and Phadia 2500/5000 instruments – Similarities to predicate devices

Feature	Predicate Device Phadia 250	New Device Phadia 2500/5000
Intended Use EliA Celikey IgG	EliA Celikey IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to tissue transglutaminase (tTG) in human serum and plasma. EliA Celikey IgG is based on recombinant human tissue transglutaminase as antigen and is useful as an aid in the clinical diagnosis of patients with Celiac disease. EliA Celikey IgG uses the EliA IgG method on the instrument ImmunoCAP 250*. (* Former name of Phadia 250)	EliA Celikey IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to tissue transglutaminase (tTG) in human serum and EDTA-plasma. EliA Celikey IgG is based on recombinant human tissue transglutaminase as antigen and is useful as an aid in the clinical diagnosis of patients with celiac disease in conjunction with other laboratory and clinical findings. EliA Celikey IgG uses the EliA IgG method on the instrument Phadia 2500/5000.
Intended Use EliA Gliadin ^{DP} IgA	EliA Gliadin ^{DP} IgA is intended for the in vitro semi-quantitative measurement of IgA antibodies directed to gliadin in human serum and plasma (heparin, EDTA, citrate) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA Gliadin ^{DP} IgA uses the EliA IgA method on the instrument Phadia 250.	EliA Gliadin ^{DP} IgA is intended for the in vitro semi-quantitative measurement of IgA antibodies directed to gliadin in human serum or plasma (Li-heparin, EDTA) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA Gliadin ^{DP} IgA uses the EliA IgA method on the instrument Phadia 2500/5000.
Intended Use EliA Gliadin ^{DP} IgG	EliA Gliadin ^{DP} IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to gliadin in human serum and plasma (heparin, EDTA, citrate) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA Gliadin ^{DP} IgG uses the EliA IgG method on the instrument Phadia 250.	EliA Gliadin ^{DP} IgG is intended for the in vitro semi-quantitative measurement of IgG antibodies directed to gliadin in human serum or plasma (Li-heparin, EDTA) to aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings. EliA Gliadin ^{DP} IgG uses the EliA IgG method on the instrument Phadia 2500/5000.

Analytical technology: Immuno-fluorescence measurement	Same	Same
Assay process	Same	Same
Common, dedicated Phadia reagents	Same	Same Introduction of new article numbers for Development Solution, Stop Solution and Washing Solution is only due to larger filling volumes which are required for the bigger instruments Phadia 2500/5000
Result calculation software; Phadia Information Data Manager (IDM)	Same	Same
Sample volume	90 µL (20 µL of non-diluted sample)	90 µL (20 µL of non-diluted sample)
Incubation temperature	37°C	37°C
Conjugate volume	90 µL	90 µL
Development Solution Volume	90 µL	90 µL
Stop Solution Volume	200 µL	200 µL
Assay set-up	Random access	Random access
Reagent packaging size	Various/Common	Various/Common Introduction of new article number for EliA Sample Diluent (83-1071-01) is only due to larger filling volume.
Onboard storage of reagents	Yes	Yes
Time to 1 st result	~2 h	~2 h

EliA Celiac Immunoassays on Phadia 250 and Phadia 2500/5000 instruments – Differences to predicate device

Feature	Predicate Device Phadia 250	New Device Phadia 2500/5000
Sample matrix; Serum or plasma type as indicated in the DFU dependent on assay	For EliA Celikey IgG: Serum or plasma (EDTA, citrate) For EliA Gliadin ^{DP} IgA and IgG: Serum or plasma (heparin, EDTA, citrate)	For EliA Celikey IgG: serum or EDTA-plasma For EliA Gliadin ^{DP} IgA and IgG: Serum or plasma (Li-heparin, EDTA)
Daily throughput	~250 tests	~2500/5000 tests
Sample Dilution	Phadia 250 uses a steel pipette to dilute the samples in Dilution Plates (Art.No. 12-3907-08)	Phadia 2500/5000 uses disposable Pipette Tips in Racks (Art No. 12-3805-04) for pipetting samples in Dilution Well (Art.No. 12-4005-69)
Risk for carry-over	The warning “DO NOT REUSE” in the Phadia 250 DFU for EliA Conjugates is due to the fact that a low risk of conjugate contamination by carry-over from samples was identified. In order to reduce the risk, the single use statement for the conjugate was included in the Phadia 250 DFU.	When running EliA tests on the Phadia 2500/5000 instruments, there is no need for this warning statement because these instruments use disposable tips for pipetting samples and a separate pipette for the conjugate, and carry-over from samples to conjugate is impossible.
Loading of EliA Carriers	EliA carriers are loaded manually on the Loading Tray from where they can be processed directly or transferred to the cooled storage compartment.	The Phadia 2500/5000 instruments do not have such a Loading Tray. The EliA carriers are loaded into racks which are directly transferred to the cooled storage compartment
Barcode reader	The Phadia 250 instrument has a built-in barcode reader at the front of the instrument, but the operator needs to scan the barcodes manually by showing the reagents to the barcode reader. Alternatively, the operator can also enter the characters below the barcode manually.	The Phadia 2500/5000 instruments dispose of a built-in barcode reader, and the reagents are on a moving belt which conveys them past the barcode reader. The lot-specific information will be read automatically by the instrument during loading.
Process time / Time to patient result	Phadia 250 needs 1 minute to process one Well. Phadia 250 provides the results at a one minute interval.	Phadia 2500/5000 instruments process two Wells in parallel in 48 seconds. Phadia 2500/5000 provides the results at a 24 seconds interval.

K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A3; Evaluation of Precision Performance of Quantitative Measurement Methods; September 2014

CLSI EP06-A Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; April 2003

CLSI EP17-A, Protocols for Determination of Limits of Detection and Limits of Quantification; October 2004.

CLSI EP09-A3, Measurement Procedure Comparison and Bias Estimation Using Patient Samples

L. Test Principle:

The EliA wells are molded cups comparable to excised wells from a microtiter plate. They are made of polystyrene and are coated with the respective antigen. The wells are at the same time a holder of the coupled antigen for convenient automation and a reaction chamber with reaction/washing solution handling based on pipetting to add and aspiration to remove liquids.

The EliA wells are coated with human recombinant tissue transglutaminase, or with synthetic deamidated gliadin peptides. If present in the patient's specimen, antibodies to these proteins bind to the specific antigen. After washing away non-bound antibodies, enzyme-labeled antibodies against human IgA or IgG antibodies (EliA IgA Conjugate or EliA IgG Conjugate) are added to form an antibody-conjugate complex. After incubation, non-bound conjugate is washed away and the bound complex is incubated with a Development Solution. After stopping the reaction, the fluorescence in the reaction mixture is measured. The higher the response value, the more specific IgA or IgG is present in the specimen. To evaluate test results, the response for patient samples is compared directly to the response for calibrators.

M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

To determine the precision of the assay, the variability was assessed in a study with a total of 21 runs (3 instruments × 7 runs).

The study was performed with 1 run/day over a period of 7 days. Each sample was tested in four replicates/run giving in total 84 replicates per sample. The data was calculated against the calibration curve from Day 1.

The results are summarized in the table below:

EliA Celikey IgG on Phadia 2500/5000

Mean (EliA U/mL)	Within-Run		Between-Run		Between-Instrument		Total Imprecision	
	SD	%CV	SD	%CV	SD	%CV	SD	%CV
1.6	0.2	10.0	0.1	7.2	0.4	25.0	0.4	27.9
7.6	0.2	2.8	0.2	3.1	0.3	4.2	0.4	5.9
9.6	0.3	2.7	0.3	2.6	0.5	5.4	0.6	6.6
104.4	2.7	2.6	3.1	3.0	3.4	3.3	5.3	5.1
274.6	8.4	3.1	6.9	2.5	9.5	3.5	14.5	5.3

EliA Gliadin^{DP} IgA on Phadia 2500/5000

Mean (EliA U/mL)	Within-Run		Between-Run		Between-Instrument		Total Imprecision	
	SD	%CV	SD	%CV	SD	%CV	SD	%CV
0.8	0.1	8.9	0.0	5.7	0.1	14.9	0.1	18.2
7.4	0.2	3.0	0.1	1.5	0.1	1.3	0.3	3.6
8.7	0.2	2.8	0.2	2.6	0.2	2.3	0.4	4.5
42.8	1.5	3.6	0.9	2.1	1.2	2.8	2.1	5.0
135.3	5.8	4.3	3.8	2.8	10.4	7.7	12.5	9.3

EliA Gliadin^{DP} IgG on Phadia 2500/5000

Mean (EliA U/mL)	Within-Run		Between-Run		Between-Instrument		Total Imprecision	
	SD	%CV	SD	%CV	SD	%CV	SD	%CV
3.6	0.3	8.2	0.2	5.2	0.3	8.6	0.5	13.0
7.2	0.2	3.3	0.4	5.4	0.2	3.1	0.5	7.0
9.3	0.3	2.8	0.5	5.2	0.0	0.0	0.5	5.9
73.7	2.6	3.5	4.9	6.7	2.2	3.0	6.0	8.1
219.6	8.2	3.7	13.2	6.0	6.8	3.1	17.0	7.7

b. Linearity/assay reportable range:

Four patient serum samples (five for Celikey IgG) were diluted in sample diluent and tested with one batch of EliA Celikey IgG, EliA Gliadin^{DP} IgA and EliA Gliadin^{DP} IgG Immunoassays and one set of system reagents on Phadia 2500/5000. The results of the regression analysis are summarized below:

EliA Celikey IgG on Phadia 2500/5000

Dilution range (EliA U/mL)	Slope	Intercept	R ²
1.3 – 35.5	1.03	0.49	0.99
1.8 – 32.9	1.02	0.69	0.99
2.2 – 196.6	1.02	1.68	1.00
7.1 – 174.0	1.01	2.26	1.00
2.8 – 227.8	1.04	2.48	0.99

The reportable range (Limit of Detection, upper limit) for EliA Celikey IgG is from 0.6 to 227 EliA U/mL. The measuring range (Limit of Quantitation, upper limit) is from 1.7 to 227 EliA U/mL.

EliA Gliadin^{DP} IgA on Phadia 2500/5000

Dilution range (EliA U/mL)	Slope	Intercept	R ²
0.4 – 28.5	1.00	-0.04	1.00
1.3 – 137.8	0.99	-1.69	1.00
0.6 – 26.9	1.00	-0.30	1.00
2.1 – 162.0	0.99	0.79	1.00

The reportable range (Limit of Detection, upper limit) for EliA Gliadin^{DP} IgA is from 0.2 to 142 EliA U/mL. The measuring range (Limit of Quantitation, upper limit) is from 0.4 to 142 EliA U/mL. Please note that concentration values between LoD and LoQ may show a higher uncertainty.

EliA Gliadin^{DP} IgG on Phadia 2500/5000

Dilution range (EliA U/mL)	Slope	Intercept	R ²
0.6 – 26.3	0.99	-0.32	1.00
0.8 – 54.4	1.00	-0.50	1.00
7.0 – 334.9	0.98	-5.65	0.99
7.3 – 288.3	1.00	1.02	1.00

The reportable range (Limit of Detection, upper limit) for EliA Gliadin^{DP} IgG is from 0.6 to 302 EliA U/mL. The measuring range (Limit of Quantitation, upper limit) is from 1.4 to 302 EliA U/mL.

Statements included in the package inserts: “Please note that concentration values between LoD and LoQ may show a higher uncertainty.”

“Please note that due to differing binding characteristics of the antibodies in patient samples, not all sera can be diluted linearly within the measuring range.”

c. *Traceability, Stability, Expected values (controls, calibrators, or methods):*

The EliA IgG method was previously reviewed in K061165.

The EliA IgA method was previously reviewed in K062787.

d. *Detection limit:*

The limit of blank (LoB), limit of detection (LoD), and limit of quantitation studies were performed on the Phadia 2500/5000 instrument. One blank sample and three low level samples were measured in thirty-three and eleven replicates, respectively, in each of two runs.

EliA Celikey IgG:

The LoD for EliA Celikey IgG is 0.6 EliA U/mL, determined consistent with the guidelines in CLSI document EP17-A2 and with proportions of false positives (α) less than 5% and false negatives (β) less than 5%; based on 132 determinations with 66 blank and 66 low level replicates; and LoB of 0.0 EliA U/mL.

Since none of those low level samples met the target level for the CV% of 20% - a requirement for the LoQ estimation – 3 additional low level samples were measured.

All low level samples were included in the LoD estimation (6 low level samples and a total of 132 determinations).

The LoQ for EliA Celikey IgG is 1.7 EliA U/mL, determined consistent with the guidelines in CLSI document EP17-A2, based on 66 determinations of 3 low level samples that are different from the ones for the determination of the LoD, and a target uncertainty goal of 20%.

The results are summarized in the table below:

EliA Celikey IgG (EliA U/mL)	LoB	LoD	LoQ
Phadia 2500/5000	0.0	0.6	1.7

EliA Gliadin^{DP} IgA:

The LoD for EliA Gliadin^{DP} IgA is 0.2 EliA U/mL, determined consistent with the guidelines in CLSI document EP17-A2 and with proportions of false positives (α) less than 5% and false negatives (β) less than 5%; based on 132 determinations with 66 blank and 66 low level replicates; and LoB of 0.0 EliA U/mL.

The LoQ for Gliadin^{DP} IgA is 0.4 EliA U/mL, determined consistent with the guidelines in CLSI document EP17-A2, based on 66 determinations, and a target uncertainty goal of 20%.

The results are summarized in the table below:

EliA Gliadin ^{DP} IgA (EliA U/mL)	LoB	LoD	LoQ
Phadia 2500/5000	0.0	0.2	0.4

EliA Gliadin^{DP} IgG:

The LoD for EliA Gliadin^{DP} IgG is 0.6 EliA U/mL, determined consistent with the guidelines in CLSI document EP17-A2 and with proportions of false positives (α) less than 5% and false negatives (β) less than 5%; based on 132 determinations with 66 blank and 66 low level replicates; and LoB of 0.3 EliA U/mL.

The LoQ for EliA Gliadin^{DP} IgG is 1.4 EliA U/mL, determined consistent with the guidelines in CLSI document EP17-A2, based on 66 determinations, and a target uncertainty goal of 20%.

The results are summarized in the table below:

EliA Gliadin ^{DP} IgG (EliA U/mL)	LoB	LoD	LoQ
Phadia 2500/5000	0.3	0.6	1.4

e. *Analytical specificity:*

Interference: Previously reviewed in K062583 and K093459.

Carry-over: Phadia 2500/5000 instruments use disposable tips for pipetting samples and a separate pipette for the conjugate, therefore carry-over from samples to conjugate is impossible.

f. *Assay cut-off:*

The ranges (negative, equivocal, positive) recommended for the evaluation of the test results were derived from the clinical studies (s. K062583 and K093459).

EliA Celikey IgG Well

< 7 EliA U/mL	Negative
7 – 10 EliA U/mL	Equivocal
> 10 EliA U/mL	Positive

EliA Gliadin^{DP} IgA Well

< 7 EliA U/mL	Negative
7 – 10 EliA U/mL	Equivocal
> 10 EliA U/mL	Positive

EliA Gliadin^{DP} IgG Well

< 7 EliA U/mL	Negative
7 – 10 EliA U/mL	Equivocal
> 10 EliA U/mL	Positive

2. Comparison studies:

a. *Method comparison with predicate device (Instrument comparison):*

See 2c Instrument Comparison below

b. *Matrix comparison:*

Previously reviewed under K062583 and K093459.

c. *Instrument comparison*

In the Method Comparison studies for the three EliA tests included in this submission, more than 100 samples ($\geq 20\%$ of the samples within $\pm 25\%$ of the medical decision point) were run in single replicates on one Phadia 250 and three Phadia 2500/5000 instruments. The acceptance criteria for the method comparison (the slope for the regression lines should be 0.9 – 1.1 for single replicate to single replicate and intercept close to 0) were met for EliA Celikey IgG, EliA Gliadin^{DP} IgA and EliA Gliadin^{DP} IgG.

EliA Celikey IgG:

Instrument	Intercept	95% CI	Slope	95% CI
PH2500/5000 A	0.49	0.26 to 0.73	0.93	0.91 to 0.94
PH2500/5000 B	0.14	-0.19 to 0.46	0.96	0.93 to 1.00
PH2500/5000 C	-0.28	-0.55 to -0.00	0.98	0.97 to 1.00

equivocal results considered positive

criteria	PH2500/5000 A	PH2500/5000 B	PH2500/5000 C
PPA	97.4%	97.4%	96.1%
95% CI	90.9% - 99.7%	90.9% - 99.7%	89.0% - 99.2%
NPA	82.6%	87.0%	91.3%
95% CI	61.2% - 95.0%	66.4% - 97.2%	72.0% - 98.9%
TPA	94.0%	95.0%	95.0%
95% CI	87.4% - 97.8%	88.7% - 98.4%	88.7% - 98.4%

equivocal results considered negative

criteria	PH2500/5000 A	PH2500/5000 B	PH2500/5000 C
PPA	95.5%	97.0%	94.0%
95% CI	87.5% - 99.1%	89.6% - 99.6%	85.4% - 98.3%
NPA	100.0%	100.0%	100.0%
95% CI	89.4% - 100.0%	89.4% - 100.0%	89.4% - 100.0%
TPA	97.0%	98.0%	96.0%
95% CI	91.5% - 99.4%	93.0% - 99.8%	90.1% - 98.9%

EliA Gliadin^{DP} IgA:

Instrument	Intercept	95% CI	Slope	95% CI
PH2500/5000 A	0.60	0.40 to 0.93	0.95	0.92 to 0.98
PH2500/5000 B	0.55	0.28 to 0.83	0.97	0.95 to 1.00
PH2500/5000 C	-0.24	-0.71 to -0.06	1.09	1.06 to 1.11

equivocal results considered positive

criteria	PH2500/5000 A	PH2500/5000 B	PH2500/5000 C
PPA	100.0%	100.0%	100.0%
95% CI	95.7% - 100.0%	95.7% - 100.0%	95.7% - 100.0%
NPA	90.5%	85.7%	90.5%
95% CI	69.6% - 98.8%	63.7% - 97.0%	69.6% - 98.8%
TPA	98.1%	97.1%	98.1%
95% CI	93.3% - 99.8%	91.9% - 99.4%	93.3% - 99.8%

equivocal results considered negative

criteria	PH2500/5000 A	PH2500/5000 B	PH2500/5000 C
PPA	98.7%	100.0%	98.7%
95% CI	93.2% - 100.0%	95.4% - 100.0%	93.2% - 100.0%
NPA	96.2%	96.2%	96.2%
95% CI	80.4% - 99.9%	80.4% - 99.9%	80.4% - 99.9%
TPA	98.1%	99.0%	98.1%
95% CI	93.3% - 99.8%	94.8% - 100.0%	93.3% - 99.8%

EliA Gliadin^{DP} IgG:

Instrument	Intercept	95% CI	Slope	95% CI
PH2500/5000 A	-0.14	-0.41 to 0.13	1.06	1.04 to 1.09
PH2500/5000 B	0.43	0.13 to 1.16	0.99	0.94 to 1.02
PH2500/5000 C	-0.06	-0.20 to 0.20	1.08	1.07 to 1.10

equivocal results considered positive

criteria	PH2500/5000 A	PH2500/5000 B	PH2500/5000 C
PPA	100.0%	100.0%	100.0%
95% CI	95.8% - 100.0%	95.8% - 100.0%	95.8% - 100.0%
NPA	89.5%	100.0%	94.7%
95% CI	66.9% - 98.7%	82.4% - 100.0%	74.0% - 99.9%
TPA	98.1%	100.0%	99.0%
95% CI	93.2% - 99.8%	96.5% - 100.0%	94.8% - 100.0%

equivocal results considered negative

criteria	PH2500/5000 A	PH2500/5000 B	PH2500/5000 C
PPA	98.8%	100.0%	100.0%
95% CI	93.2% - 100.0%	95.5% - 100.0%	95.5% - 100.0%
NPA	100.0%	95.8%	91.7%
95% CI	85.8% - 100.0%	78.9% - 99.9%	73.0% - 99.0%
TPA	99.0%	99.0%	98.1%
95% CI	94.8% - 100.0%	94.8% - 100.0%	93.2% - 99.8%

3. Clinical studies:

a. Clinical sensitivity:

Not applicable.

b. Clinical specificity:

Not applicable.

c. Other clinical supportive data (when a. and b. are not applicable):

Clinical performance values were reviewed in K062583 and K093459.

4. Clinical cut-off:

Same as assay cut-off.

5. Expected values/Reference range:

The frequency distribution for anti-tTG IgG and anti-gliadin IgA and IgG antibodies was investigated in a group of apparently healthy subjects equally distributed by age and gender, using sera from a Caucasian population obtained from a blood bank.

The results are given in the table below:

Test	n =	Median (EliA U/mL)	95th percentile	99th percentile
EliA Celikey IgG on Phadia 2500/5000	400	2.3	3.3	3.9
EliA Gliadin ^{DP} IgA on Phadia 2500/5000	400	1.4	3.8	7.1
EliA Gliadin ^{DP} IgG on Phadia 2500/5000	400	0.9	2.7	13.3

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

All available data support that both instrument platforms, Phadia 250 and Phadia 2500/5000 perform substantially equivalent when using the EliA Celikey IgG, EliA Gliadin^{DP} IgA and EliA Gliadin^{DP} IgG immunoassays.

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.